Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 9, 9, 34, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 7 molecules, respectively.
Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Adiso Therapeutics Inc
Affinivax Inc
Appili Therapeutics Inc
Ascendo Biotechnology Inc
Biomica
Botanix Pharmaceuticals Ltd
Boulos and Cooper Pharmaceuticals Pty Ltd
Cambimune Ltd
Chain Biotechnology Ltd
Crestone Inc
CSA Biotechnologies LLC
Daiichi Sankyo Co Ltd
Deinove SAS
Destiny Pharma Plc
Enterobiotix Ltd
Facile Therapeutics Inc
Finch Therapeutics Group Inc
First Wave BioPharma Inc
Fzata Inc
Gateway Pharmaceutical LLC
GSK plc
Idorsia Pharmaceutical Ltd
Immune Biosolutions Inc
ImmuneBiotech AB
ImmuniMed Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
KamTek Inc
Kowa Co Ltd
Lumen Bioscience Inc
Malachite Innovations Inc
Mapp Biopharmaceutical Inc
Matrivax Research & Development Corp
MGB Biopharma Ltd
Microbiotica Ltd
Micropharm Ltd
Mikrobiomik Healthcare Company SL
MV BioTherapeutics SA
MyBiotics Pharma Ltd
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Nubiyota LLC
Oragenics Inc
Ostrich Pharma USA Inc
PanTheryx Inc
Pfizer Inc
Proxi Biotech IVS
Pylum Biosciences Inc
Q2 Pharma Ltd
QureTech Bio AB
Rebiotix Inc
Rebus Holdings Inc
Recursion Pharmaceuticals Inc
Sano Chemicals Inc
Scioto Biosciences Inc
Secretory IgA Inc
Seres Therapeutics Inc
Servatus Ltd
Summit Therapeutics Inc
Symbiotic Health Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Vedanta Biosciences Inc
Versatope Therapeutics Inc
Vifor Pharma Ltd
XBiotech Inc
Zhiyi Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.